Suchergebnisse - "Pandya, Bhavik J"

PubPharm (52)

1

Clinical outcomes and treatment patterns in adults with FLT3-ITDmut+ acute myeloid leukemia undergoing allogeneic hemopoietic cell transplantation in the US and Canada

enthalten in: Transplantation and cellular therapy | 2024

von Pandya, B. | Burns, L. | Wang, T. | +6

2

Work absenteeism, disability, and lost wages among patients with acute myeloid leukemia and their caregivers : a cohort study using US administrative claims and productivity data

enthalten in: Expert review of pharmacoeconomics & outcomes research | 2024

von Pandya, B. | Young, C. | Packnett, E. | +6

3

Healthcare resource utilization and costs during first salvage therapy for relapsed or refractory acute myeloid leukemia in the United States

enthalten in: Leukemia & lymphoma | 2023

von Muffly, L. | Young, C. | Feng, Q. | +2

4

The experience of patients with acute myeloid leukemia in remission post-transplant

enthalten in: Leukemia & lymphoma | 2023

von Cella, D. | Kelly, K. | de la Motte, A. | +4

5

Patient-reported outcomes from the phase 3 ADMIRAL trial in patients with FLT3-mutated relapsed/refractory AML

enthalten in: Leukemia & lymphoma | 2023

von Ritchie, E. | Cella, D. | Fabbiano, F. | +5

CommentIn: Leuk Lymphoma. 2023 May;64(5):910-912. - PMID 37166176

6

Patient and Physician Preferences for Acute Myeloid Leukemia Maintenance Treatments Following Hematopoietic Stem Cell Transplantation

enthalten in: Patient preference and adherence | 2023

von Saini, L. | Griffin, J. | Pandya, B. | +5

7

Burden of chemotherapy in patients with relapsed/refractory acute myeloid leukemia in the United States : a retrospective claims database study

enthalten in: Expert review of hematology | 2022

von Pandya, B. | Chen, C. | McGuiness, C. | +4

8

Gilteritinib vs salvage chemotherapy in FLT3-mutated acute myeloid leukemia : number needed to treat for clinical outcomes per a secondary analysis of the ADMIRAL trial

enthalten in: Leukemia & lymphoma | 2022

von Zeidan, A. | Qi, C. | Yang, H. | +3

9

Cost-effectiveness of gilteritinib for relapsed/refractory FLT3mut+ acute myeloid leukemia

enthalten in: Journal of managed care & specialty pharmacy | 2021

von Pandya, B. | Qi, C. | Garnham, A. | +3

10

A budget impact analysis of gilteritinib for the treatment of relapsed or refractory FLT3 mut+ acute myeloid leukemia in a US health plan

enthalten in: Journal of medical economics | 2021

von Pandya, B. | Yang, H. | Schmeichel, C. | +2

1
2
3
4
5
6
Nächster »
[6]